A pneumothorax is an abnormal collection of air in the pleural space between the lung and the chest wall. Symptoms typically include sudden onset of sharp, one-sided chest pain and shortness of breath. In a minority of cases, a one-way valve is formed by an area of damaged tissue, and the amount of air in the space between chest wall and lungs increases; this is called a tension pneumothorax. This can cause a steadily worsening oxygen shortage and low blood pressure. This leads to a type of shock called obstructive shock, which can be fatal unless reversed. Very rarely, both lungs may be affected by a pneumothorax. It is often called a "collapsed lung", although that term may also refer to atelectasis.A primary spontaneous pneumothorax is one that occurs without an apparent cause and in the absence of significant lung disease. A secondary spontaneous pneumothorax occurs in the presence of existing lung disease. Smoking increases the risk of primary spontaneous pneumothorax, while the main underlying causes for secondary pneumothorax are COPD, asthma, and tuberculosis. A traumatic pneumothorax can develop from physical trauma to the chest (including a blast injury) or from a complication of a healthcare intervention.Diagnosis of a pneumothorax by physical examination alone can be difficult (particularly in smaller pneumothoraces). A chest X-ray, computed tomography (CT) scan, or ultrasound is usually used to confirm its presence. Other conditions that can result in similar symptoms include a hemothorax (buildup of blood in the pleural space), pulmonary embolism, and heart attack.
"Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats". Neurosci. Lett. 434 (1): 66–70. doi:10.1016/j.neulet.2008.01.032. PMID 18281154. S2CID 7754768. Mochel F, DeLonlay P, Touati G, Brunengraber H, Kinman RP, Rabier D,  et al. (April 2005). "Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy". Mol. Genet. Metab. 84 (4): 305–12. doi:10.1016/j.ymgme.2004.09.007. PMID 15781190. Borges K, Sonnewald U (July 2012). "Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?". Epilepsy Res. 100 (3): 239–44. doi:10.1016/j.eplepsyres.2011.05.023. PMC 3422680. PMID 21855298. External links
"Triheptanoin". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT01379625 for "Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder (Triheptanoin)" at ClinicalTrials.gov